Supplementary Table S1. Dose Modification for Specific Adverse Reactions Listed in at Least One CDK4/6i Product Monograph

	Grade 1	Grade 2	Grade 3	Grade 4
Neutropenia	ANC 1000/mm^3 –<LLN No modification	ANC 500/mm^3–<1000/mm^3 Interrupt until Grade ≤2 and resume at same dose *Recurrent or febrile neutropenia*: Interrupt until Grade ≤2 and resume at next lower dose PAL: As above if Day 1 of cycle; if Day 15 of first 2 cycles, continue at current dose and adjust based on CBC repeated Day 22	ANC <500/mm^3 Interrupt until Grade ≤2 and resume at next lower dose	
ALT/AST elevations without increase in total bilirubin >2x ULN No specific PAL recommendations	ALT/AST >ULN–3x ULN No modification	ALT/AST >3x–5x ULN RIB: if BL <Grade 2, interrupt until recover to BL, then resume at same dose If BL Grade 2, no modification ABE: No modification *Recurrent*: Interrupt until ≤BL (ABE, RIB) or Grade 1 (ABE) and resume at next lower dose	ALT/AST >5–20x ULN Interrupt until ≤BL (ABE, RIB) or Grade 1 (ABE) and resume at next lower dose	ALT/AST >20x ULN Discontinue
Total bilirubin >2 x ULN No specific PAL recommendations		ALT/AST >3x ULN Discontinue		
QTcF prolongation + electrolytes No specific PAL or ABE recommendations		QTcF >480 ms or recurrent ≥481 ms Interrupt until <481 ms then resume at next lower dose Correct serum electrolytes before resuming	QTcF >500 ms Interrupt until <481 ms then resume at next lower dose Correct serum electrolytes before resuming	Torsade de Pointes; polymorphic ventricular tachycardia; unexplained syncope; signs / symptoms of serious arrhythmia Permanently discontinue
Diarrhea No specific RIB or PAL recommendations	Increase of <4 stools/day over BL No modification	Increase of 4–6 stools/day over BL Does not resolve within 24 hours to ≤Grade 1: suspend until resolution; no modification *Persistent / recurrent after resuming despite maximal supportive measures:* suspend until ≤Grade 1; resume at next lower dose	≥7 stools/day over BL; hospitalization; life-threatening consequences Suspend until ≤Grade 1; resume at next lower dose	
ILD / pneumonitis	Grade 1 (asymptomatic) No modification* No specific PAL recommendations	Grade 2 (symptomatic) No modification *Persistent (7 days) / recurrent despite maximal supportive measures:* suspend until BL (ABE) or ≤Grade 1 (ABE, RIB) and resume at next lower dose† No specific PAL recommendations	Grade 3 or 4 (severe) Discontinue	
VTE (advanced breast cancer) No specific RIB or PAL recommendations	Grade 1 No modification	Grade 2 No modification	Grade 3 or 4 Suspend dose and treat as clinically indicated; resume when patient is clinically stable	

*The ribociclib product monograph recommends initiating appropriate medical therapy and monitoring as clinically indicated.

[†]The ribociclib product monograph recommends performing an individualized benefit-risk assessment when considering resuming.